<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[VDYNE, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=50485></link><description><![CDATA[VDYNE, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Wed, 20 May 2026 06:55:52 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2026/04/12_1028147215_20260403112947_1731496695.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[VDYNE Receives FDA Approval to Initiate the TRIVITA[1] IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1031711</link><description><![CDATA[MAPLE GROVE, Minn.--(Business Wire/Korea Newswire)--VDYNE, Inc. (“VDYNE” or “the Company”), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food &amp; Drug Administration (FDA) has approved an investigational device exemption (IDE) for the company’s pivotal clinical trial evaluating its Transcatheter Tr...]]></description><pubDate>Fri, 03 Apr 2026 13:30:00 +0900</pubDate></item><item><title><![CDATA[브이다인, 경도자 삼첨판 치환술 시스템의 ‘트리비타[1]’ IDE 확증 임상시험 개시에 대한 FDA 승인 획득]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1031712</link><description><![CDATA[메이플 그로브, 미네소타--(Business Wire/뉴스와이어)--차세대 경도자 판막 치환술 기술을 개발하는 비상장 의료기기 기업인 브이다인(VDYNE, Inc.)은 미국 식품의약국(FDA)으로부터 자사의 경도자 삼첨판 치환술(Transcatheter Tricuspid Valve Replacement, TTVR) 시스템을 평가하는 확증 임상시험에 대한 임상시험용 기기 면제(Investigational Device Exemption, IDE) 승인을 받았다고 발표했다.  이번 IDE 승인으로 브이다인...]]></description><pubDate>Fri, 03 Apr 2026 13:30:00 +0900</pubDate></item></channel></rss>